Nucynta (tapentadol immediate release tablets) has been made available by PriCara, a division of Ortho-McNeil Janssen, for the treatment of moderate to severe acute pain in patients ≥18 years old. Nucynta exerts its analgesic effects by binding to mu-opioid receptors and inhibiting norepinephrine reuptake. It was originally approved by the FDA in November 20, 2008. This approval was based on data from clinical trials involving more than 2,100 patients with acute pain, which found that Nucynta provided significant relief of moderate to severe acute pain compared to placebo.

Nucynta is a C-II controlled substance. It is available in 50mg, 75mg, and 100mg dosage strengths.

For more information call (800) 526-7736 or visit